Here Futura Medical PLC (AIM:FUM, OTC:FAMDF) CEO James Barder discusses the UK launch of Eroxon, the company's over-the-counter erectile dysfunction treatment, with Thomas Warner of Proactive.
Eroxon is now available at Boots stores and online. Barder highlighted the importance of respecting commercial partners' wishes, noting that updates will be provided reactively rather than proactively.
Mosman Oil and Gas Ltd (AIM:MSMN) has updated investors on its ongoing corporate review, undertaken because the company believes its asset’s value isn’t being properly reflected in its share price.
The company, which has producing assets in the United States and exploration projects in Australia, in a statement, said talks are ongoing with various parties interested in its assets, and, any resulting commercial proposals will be assessed by the board.
Primary Health Properties PLC (LSE:PHP, OTC:PHPRF) (PHP) has reported 0.9% growth from its rent review and asset management activities in the first-quarter of 2023, generating an extra £1.3mln on a like-for-like basis compared to the first quarter of 2021.
In a trading update. the modern healthcare facilities investor said settled rent reviews generated £1.2mln, primarily driven by the impact of inflation on both indexed-linked and open market value (OMV) reviews, while asset management activities generated an additional £100,000, with three new projects due to start shortly.
Genflow Biosciences PLC (LSE:GENF) has applied to trade the company's shares on the US OTCQB Venture Market.
By doing so, Genflow aims to broaden its reach to more investors and potentially enhance liquidity in its stock.
Faron Pharmaceuticals Limited (AIM:FARN, OTC:FPHAF) has announced plans to host a virtual event via webcast on Tuesday, 25 April, to discuss its progress in developing novel immunotherapies for the treatment of cancers.
The event will feature Dr Naval Daver, associate professor of Leukemia at The University of Texas MD Anderson Cancer Center, and Dr Mika Kontro, associate professor at the University of Helsinki, who will provide an update on the most recent Phase I/II BEXMAB data in AML and MDS patients.
Atlantic Lithium Limited (AIM:ALL, OTCQX:ALLIF, ASX:A11) has started infill programmes at Ewoyaa in Ghana comprising 3,000 metres (m) of reverse circulation and diamond drilling with a passive seismic survey also underway.
Lennard Kolff, interim chief executive, said the exploration aims to de-risk the project's current resources further and add optionality to the mine plan.
ANGLE PLC (AIM:AGL, OTCQX:ANPCY), the liquid biopsy company, has announced a partnership with BioView, a developer and marketer of automated cell imaging and analysis solutions, to create a circulating tumour cell (CTC) HER2 assay for breast cancer.
The test will utilise ANGLE's FDA-cleared Parsortix PC1 Clinical System and BioView's automated microscopy systems and software, and is expected to generate around £1.2mln in revenues for the London-listed group.
Allergy Therapeutics PLC (AIM:AGY, OTC:AGYTF) has announced a significant milestone in its innovative peanut allergy treatment with the successful completion of skin-prick testing on peanut-allergic patients in the phase I PROTECT clinical trial.
The results indicate a substantial reduction in skin reactivity for the company's VLP Peanut vaccine compared to standard peanut extract.
ImmuPharma PLC (AIM:IMM, OTC:IMMPF) has confirmed a Type-C meeting is scheduled with the US Food and Drug Administration (FDA) for 7 June.
Scientists will discuss the upcoming phase II/III adaptive study of Lupuzor (also known as P140) in systemic lupus erythematosus patients. This development follows the company's recent announcement on 27 March 2023.
One of the world’s largest graphene-enhanced green cement trials is set to start in June as First Graphene Ltd (ASX:FGR, OTCQB:FGPHF) leads a consortium to investigate a simple, low-cost method of introducing graphene to industrial-scale cement processes.
“Our research and development in collaboration with some of the world’s most innovative materials technology organisations, coupled with buy-in from industry partners to trial our graphene products, sets the foundation for a strong commercialisation pathway,” First Graphene managing director and CEO Michael Bell said.